Romiplostim ở bệnh nhân trải qua ghép tế bào gốc huyết học: kết quả của thử nghiệm đa tâm giai đoạn 1/2

Blood - Tập 135 - Trang 227-229 - 2020
Régis Peffault de Latour1,2, Sylvie Chevret2,3, Anna Lisa Ruggeri4,5, Felipe Suarez6, Laetitia Souchet7, David Michonneau1, Flore Sicre de Fontbrune1, Tereza Coman1, Nathalie Dhedin1, Marie Thérèse Rubio8,9, Stéphanie Nguyen7,8,9, Mohamad Mohty4,8,9,10, Gérard Socié1,2
1Bone Marrow Transplantation Unit, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
2Université de Paris, Paris, France
3Biostatistic Unit, Saint Louis Hospital, Paris, France
4Hematology and Cell Therapy Unit, Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
5Department of Pediatric Hematology and Oncology, Istituto Di Ricovero e Cura a Carattere Scientifico, Bambino Gesu Pediatric Hospital, Rome, Italy
6Bone Marrow Transplantation Unit, Necker Hospital, Paris
7Bone Marrow Transplantation Unit, Pitié Salpetrière Hospital, Assistance Publique Hôpitaux de Paris, Paris
8Hematology Department, Bone Marrow Transplantation Unit, Nancy, France
9Sorbonne Université, Paris, France
10INSERM Unite Mixte de Recherche 938, Paris, France

Tóm tắt

Tình trạng giảm tiểu cầu nặng kéo dài hơn 6 tuần sau khi ghép tế bào gốc đồng loại là một vấn đề phổ biến liên quan đến tiên lượng xấu. Peffault de Latour và cộng sự báo cáo kết quả của thử nghiệm đầu tiên về thuốc mimetic thrombopoietin, romiplostim, trong bối cảnh này, cho thấy sự phục hồi số lượng tiểu cầu ở 18 trong số 24 bệnh nhân.

Từ khóa


Tài liệu tham khảo

Nash, 1996, The problem of thrombocytopenia after hematopoietic stem cell transplantation, Oncologist, 1, 371, 10.1634/theoncologist.1-6-371 Yamazaki, 2006, Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover, Bone Marrow Transplant, 38, 377, 10.1038/sj.bmt.1705444 Liesveld, 2013, A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation, Biol Blood Marrow Transplant, 19, 1745, 10.1016/j.bbmt.2013.10.002 Tang, 2018, Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag, J Hematol Oncol, 11, 103, 10.1186/s13045-018-0649-6 Master, 2018, Use of eltrombopag in improving poor graft function after allogeneic hematopoietic stem cell transplantation, Case Rep Oncol, 11, 191, 10.1159/000487229 Hartranft, 2017, Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients, J Oncol Pharm Pract, 23, 10, 10.1177/1078155215612240 Battipaglia, 2015, Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation, Bone Marrow Transplant, 50, 1574, 10.1038/bmt.2015.182 Tanaka, 2016, Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 22, 919, 10.1016/j.bbmt.2016.01.018 Reid, 2012, Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia, Am J Hematol, 87, 743, 10.1002/ajh.23225 Kuter, 2009, Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim, Blood, 114, 3748, 10.1182/blood-2009-05-224766 Olnes, 2012, Eltrombopag and improved hematopoiesis in refractory aplastic anemia, N Engl J Med, 367, 11, 10.1056/NEJMoa1200931 Desmond, 2014, Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug, Blood, 123, 1818, 10.1182/blood-2013-10-534743 Stasia, 2014, CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 20, 1440, 10.1016/j.bbmt.2014.05.016